SEC Form 4 · accession 0001104659-16-145191
Vitae Pharmaceuticals, Inc · VTAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey S. Hatfield
Officer — Chief Executive Officer · Director
Period of report
Sep 14, 2016
Accepted (ET)
Sep 16, 2016 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157602
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 14, 2016 | S | 50,000 | $20.81 | D | 244,996 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2015.